Research

The University of Colorado Hemophilia and Thrombosis Center (CU HTC) integrates comprehensive patient care with pioneering research. Every study we conduct is driven by a simple mission – to improve the lives of people with bleeding and clotting disorders. We welcome patients, families, and scientific collaborators alike to explore how our research is advancing treatment and understanding of these conditions.

Our Research Objectives:

1. Provide patients with opportunities to participate in clinical trials for new or existing therapies to treat bleeding and clotting disorders.
2. Conduct high impact research that advances the mechanistic understanding, diagnosis, and treatment of bleeding and clotting disorders. 
3. Partner with campus, regional, national, and international partners to leverage unique biorepositories, techniques, and expertise at the CU HTC.

Our research is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) under grant number H30MC24049 Hemophilia Treatment Centers (SPRANS) and several state, federal, and foundation awards to individual investigators.